Tizanidine Tablet
Product Images NDC 16714-172

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 16714-172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Container1 (Container1)
This is a description of Tizanidine tablets, USP. Each tablet contains 2.288 mg Tizanidine hydrochloride USP, equivalent to 2mg Tizanidine base. It is important to note that Tizanidine tablets are not interchangeable with Tizanidine capsules. These tablets come in a pack of 150 and the prescribing information can be found in the package insert. The tablets should be stored at a temperature of 25°C (77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Northstar Rx LLC is the manufacturer, located in Memphis, TN, while Dr. Reddy's Laboratories Limited, located in Sikakulam - 532 409 India, is the distributor. The product is labeled with a GTIN number of 0031671417.*
FDA Label Image

Container2 (Container2)

Container2 (Container2)
This is a description of Tizanidine, a USP tablet medication sold in a bottle containing 150 tablets. It is important to keep it away from children and stored between 15-30 °C. The manufacturer is Northstar Rx LLC, located in Memphis, TN and it was made by Dr. Reddy's Laboratories Limited in India. Each tablet in the bottle contains 4mg of Tizanidine Hycrochioride USP. It is not interchangeable with Tizanidine Capsules. Further prescribing information is available in the package insert.*
FDA Label Image

Fig1 (Fig1)

FDA Label Image

Fig2 (Fig2)

FDA Label Image

Fig3 (Fig3)

Fig3 (Fig3)
The text describes the improvement of Ashworth score in a study that involved the administration of zanidine. The study lasted for 7 weeks, and the Ashworth score was measured at week 3 and at the end of maintenance endpoint. The mean dose of zanidine used in the study was 28.6 mg.*
FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.